Key result
BlueDop device emerges as a novel tool for detecting PAD, potentially overcoming ABPI limitations.
Why the study?
Does the BlueDop device improve the detection of lower limb arterial disease compared to the ankle-brachial pressure index in patients with suspected peripheral arterial disease?
Observational
Does the BlueDop device improve the detection of lower limb arterial disease compared to the ankle-brachial pressure index in patients with suspected peripheral arterial disease?
The BlueDop device is introduced as a novel assessment tool for detecting lower limb arterial disease, potentially overcoming the limitations of the ankle-brachial pressure index in specific patient populations.
Answers are grounded in this paper and cite their sources.
BlueDop should not yet change practice; leaves open its detection advantage over ABPI in suspected peripheral arterial disease.
According to National Institute of Clinical Excellence guidelines, the ankle-brachial pressure index coupled with a full clinical evaluation has been the mainstay of detecting peripheral arterial disease on its suspicion. However, this technique is not free of its own limitations in calcified arteries, ulcerative and diabetic patients. We introduce a new, novel, and effective assessment device (BlueDop) with a minimal learning curve that could overcome such barriers and serve as a valid replacement in perihospital settings.
No takes yet. Share an insight, caveat, or question.
Kordzadeh et al. (2017) conducted an observational in Lower Limb Arterial Disease. BlueDop device vs. Ankle-brachial pressure index was evaluated on Detection of peripheral arterial disease. The BlueDop device was introduced as a novel assessment tool for detecting lower limb arterial disease, potentially overcoming limitations of the ankle-brachial pressure index.
Synapse has enriched 10 related papers. Consider them for comparative context: